Applitech Biological Technology Files for IPO, Showcasing Leadership in Biopharmaceutical Process Solutions at CSGCT 2025

Guangzhou Abiotech Co., Ltd.

Abbreviation: Abeitai

Booth Number: A02

Applitech Biological Technology Co., Ltd. is a high-tech enterprise integrating design, R&D, production, sales, and service, dedicated to providing professional production and analytical equipment, single-use consumables, and comprehensive solutions for the biopharmaceutical industry. Since our inception, we have remained customer-centric, adhering to the business principle of “Quality First, Service Foremost.” Focusing on the optimization, scale-up, and production of bioprocesses, we continuously refine our product portfolio in the biopharmaceutical sector to deliver comprehensive professional bioprocessing solutions, empowering our customers to achieve new breakthroughs in the field.

iBET Deep DiveBioreactorWith nearly two decades of expertise in the field, we are committed to developing high-end, independently manufactured bioreactors. Our bioreactor portfolio spans R&D, pilot-scale, and cGMP manufacturing, and is widely applied in the development and production of antibodies, vaccines, cell therapies, gene therapies, and stem cell therapies. Centered on bioreactors as our core business, we have gradually established a comprehensive product lineup that includes process monitoring, spectroscopic analysis, cell analysis, online sampling, and sample processing, providing extensive products and technical services to biopharmaceutical companies both in China and abroad.

Abet’s sales and after-sales service network covers China. Headquartered in Guangzhou, the company has established branches and product display and application centers in Shanghai and Beijing, representative offices in Chengdu, Xi’an, and other cities, and service points in Tianjin, Suzhou, Hangzhou, Wuhan, Nanjing, Lanzhou, Changchun, Qingdao, and other locations. Upholding the service philosophy of “professional expertise, attentive service, and rapid response,” Abet is customer-oriented and works closely with technical partners to jointly safeguard the development of the biopharmaceutical industry.

Product Features:

● Patented 24-channel microfluidic consumables

● Pre-embedded AOPI fluorescent dye

● Automated mixing and staining technology to reduce manual errors

● 24 samples in just 17 minutes, <50 seconds/sample

● Low sample volume required, only 40 μL

● No cleaning required, zero maintenance

● Audit trail permission management, compliant with21 CFR Part 11

Product Features:

● Simple operation, no flow cytometry experience or dedicated personnel required

● High-throughput analysis, capable of analyzing 8 samples at a time

● Rapid analysis: 8 samples in just 1–2 minutes

● Low sample volume required: only 15 μL per sample

● No cleaning, calibration, or maintenance required

● Compliant with 21 CFR Part 11

To promote ChinaCGTTechnological breakthroughs, industrial integration, policy alignment, and international cooperation in the field have propelled China’s CGT industry to the forefront of global competition, giving rise to the China Society for Gene and Cell Therapy (CSGCT) Conference.

Building on its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring togetherTop global scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions bring the most advanced developments in the global field of cell and gene therapy.Cutting-edge research advancements, technologies and applications, market access information, high-quality collaborative projects, and matchmaking with overseas investors and investment opportunities, building a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, with sessions designed to1 Main Forum + 15 High-End Sub-Forums, coveringLatest advances in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, and tumor vaccines, as well as CMC and testing, AI-driven drug discovery, registration and regulation, and investment, financing, and BD matchmakingWaitComprehensive coverage of the entire industry chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, please scan the QR code to visit the official conference website.